Another member of the MAPK pathway, the GTPase NRAS, is observed to be mutated in about 30% of all melanoma cases, with the most common mutations in either exon 1 (G12 or G13) or exon 2 (Q61). The gene discussed is NRAS; the disease is melanoma.